Literature DB >> 30533776

Complete Genome Sequence of Bacillus subtilis Strain WB800N, an Extracellular Protease-Deficient Derivative of Strain 168.

Haeyoung Jeong1,2, Da-Eun Jeong1, Seung-Hwan Park1,2, Seong Joo Kim3, Soo-Keun Choi1,2.   

Abstract

Bacillus subtilis WB800N is a genetically engineered variant of B. subtilis 168, such that all extracellular proteases are disrupted, which enables WB800N to be widely used for the expression of secretory proteins. Here, we report the 4.2-Mb complete genome sequence of WB800N and present all of the disrupted gene structure.

Entities:  

Year:  2018        PMID: 30533776      PMCID: PMC6256541          DOI: 10.1128/MRA.01380-18

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

Bacillus subtilis has many advantages as a protein expression host, such as its generally recognized as safe (GRAS) status, easy genetic manipulation, well-known large-scale fermentation process, and protein secretion into media. However, the expression of recombinant secretory proteins in B. subtilis has often been unsuccessful due to the degradation of secreted proteins by extracellular proteases (1). B. subtilis has eight extracellular proteases, known as NprE, AprE, Epr, Bpr, Mpr, NprB, Vpr, and WprA. To increase the stability of secreted proteins, the eight-extracellular-protease-deficient mutant WB800N was constructed (2) and is commercially available. However, since it was constructed over a long period of time, it is not easy to follow the construction process in order to know the accurate genetic structure of the extracellular protease genes on the genome. Furthermore, the insertion locus of the kanamycin resistance gene is unclear. To clarify this uncertainty, we determined the complete genome sequence of B. subtilis WB800N for further strain improvement. WB800N cells (catalog no. PBS022) were purchased from MoBiTec (Göttingen, Germany) and were grown aerobically in Luria-Bertani (LB) medium at 37°C. Genomic DNA was extracted using a Wizard genomic DNA purification kit from Promega (Wisconsin, USA) according to the manufacturer’s instructions. Library construction and genome sequencing were carried out on a PacBio RS II platform at Chun Lab (Seoul, Republic of Korea) using P6-C4 chemistry. Using the RS_HGAP_Assembly.3 protocol in SMRT Analysis v2.3 (https://www.pacb.com/products-and-services/analytical-software/smrt-analysis/), 73,369 reads totaling 361.44 Mb (81.3× genome coverage and an N50 read length of 7,290 bp) were assembled into two contigs of 4.23 Mb and 1.88 kb. The smaller contig was discarded because it was found to be the PacBio internal control DNA. The chromosomal sequence, corrected through two consecutive rounds of the RS_Resequencing.1 protocol in SMRT Analysis, was circularized using Circlator (3). The final sequence consists of a chromosome of 4,214,174 bp with a G+C content of 43.5%. Genome annotation was carried out using NCBI’s Prokaryotic Genome Annotation Pipeline (PGAP) v4.6 (4). Compared to the genome sequence of B. subtilis strain 168 (GenBank accession no. NC_000964.3) using Cross_match (http://www.phrap.org/), all alignment blocks were nearly identical with each other (0 to 0.01% nucleotide difference), and they were placed collinearly along the chromosome. Unaligned regions at the boundaries of each block are due to the genetic manipulations in the WB800N strain. Compared to strain 168, the gene structure changes of WB800N are as follows. The nprE, aprE, bpr, vpr, and epr genes were partially deleted without insertion of the antibiotic resistance gene, while wprA and nprB were disrupted by the hygromycin resistance gene and the blasticidin resistance gene, respectively. The entire mpr gene was deleted and replaced by the bleomycin resistance gene. In the middle of the ispA gene, a large DNA fragment containing an rsbRB, a C-terminal fragment of a tetracycline resistance gene, a separated chloramphenicol resistance gene, a kanamycin resistance gene, an ampicillin resistance gene, and an N-terminal fragment of metE were inserted (Fig. 1). The genome information will be useful for further improvement of the strain.
FIG 1

Comparison of protease gene structure in the genome between B. subtilis strains 168 and WB800N. The numbers indicate the distance from the translation start sites (+1). Resistance gene abbreviations: ble, bleomycin; bsr, blasticidin; hyg, hygromycin; tet, tetracycline; cat, chloramphenicol; kan, kanamycin; amp, ampicillin. Bold numbers represent the locus tag for each gene within the genome sequence.

Comparison of protease gene structure in the genome between B. subtilis strains 168 and WB800N. The numbers indicate the distance from the translation start sites (+1). Resistance gene abbreviations: ble, bleomycin; bsr, blasticidin; hyg, hygromycin; tet, tetracycline; cat, chloramphenicol; kan, kanamycin; amp, ampicillin. Bold numbers represent the locus tag for each gene within the genome sequence.

Data availability.

This genome sequencing project has been deposited in DDBJ/ENA/GenBank under the accession no. CP032310. The version described in this paper is the first version (CP032310.1). Raw sequencing reads are available in NCBI under BioProject accession no. PRJNA490410.
  4 in total

Review 1.  Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism.

Authors:  Lidia Westers; Helga Westers; Wim J Quax
Journal:  Biochim Biophys Acta       Date:  2004-11-11

2.  Analysis and application of Bacillus subtilis sortases to anchor recombinant proteins on the cell wall.

Authors:  Hoang Duc Nguyen; Trang Thi Phuong Phan; Wolfgang Schumann
Journal:  AMB Express       Date:  2011-07-21       Impact factor: 3.298

3.  Circlator: automated circularization of genome assemblies using long sequencing reads.

Authors:  Martin Hunt; Nishadi De Silva; Thomas D Otto; Julian Parkhill; Jacqueline A Keane; Simon R Harris
Journal:  Genome Biol       Date:  2015-12-29       Impact factor: 13.583

4.  NCBI prokaryotic genome annotation pipeline.

Authors:  Tatiana Tatusova; Michael DiCuccio; Azat Badretdin; Vyacheslav Chetvernin; Eric P Nawrocki; Leonid Zaslavsky; Alexandre Lomsadze; Kim D Pruitt; Mark Borodovsky; James Ostell
Journal:  Nucleic Acids Res       Date:  2016-06-24       Impact factor: 16.971

  4 in total
  8 in total

1.  Enhanced extracellular raw starch-degrading α-amylase production in Bacillus subtilis by promoter engineering and translation initiation efficiency optimization.

Authors:  He Li; Dongbang Yao; Yan Pan; Xin Chen; Zemin Fang; Yazhong Xiao
Journal:  Microb Cell Fact       Date:  2022-06-27       Impact factor: 6.352

2.  Engineering Bacillus subtilis as a Versatile and Stable Platform for Production of Nanobodies.

Authors:  Mengdi Yang; Ge Zhu; George Korza; Xin Sun; Peter Setlow; Jiahe Li
Journal:  Appl Environ Microbiol       Date:  2020-04-01       Impact factor: 4.792

3.  Cell Factory Engineering of Undomesticated Bacillus Strains Using a Modified Integrative and Conjugative Element for Efficient Plasmid Delivery.

Authors:  Da-Eun Jeong; Man Su Kim; Ha-Rim Kim; Soo-Keun Choi
Journal:  Front Microbiol       Date:  2022-04-26       Impact factor: 6.064

4.  Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency.

Authors:  Yeonsu Oh; Jung Ae Kim; Chang-Hwan Kim; Soo-Keun Choi; Jae-Gu Pan
Journal:  BMC Vet Res       Date:  2020-07-28       Impact factor: 2.741

5.  A Complete Genome Sequence of the Wood Stem Endophyte Bacillus velezensis BY6 Strain Possessing Plant Growth-Promoting and Antifungal Activities.

Authors:  Ping Zhang; Jian Diao; Guangqiang Xie; Ling Ma; Lihai Wang
Journal:  Biomed Res Int       Date:  2021-01-30       Impact factor: 3.411

Review 6.  The ins and outs of Bacillus proteases: activities, functions and commercial significance.

Authors:  Colin R Harwood; Yoshimi Kikuchi
Journal:  FEMS Microbiol Rev       Date:  2022-01-18       Impact factor: 16.408

7.  Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate.

Authors:  Johnny Chun-Chau Sung; Ying Liu; Kam-Chau Wu; Man-Chung Choi; Chloe Ho-Yi Ma; Jayman Lin; Emily Isabel Cheng He; David Yiu-Ming Leung; Eric Tung-Po Sze; Yusuf Khwaja Hamied; Dominic Man-Kit Lam; Keith Wai-Yeung Kwong
Journal:  Vaccines (Basel)       Date:  2021-12-21

8.  IPA-3: An Inhibitor of Diadenylate Cyclase of Streptococcus suis with Potent Antimicrobial Activity.

Authors:  Haotian Li; Tingting Li; Wenjin Zou; Minghui Ni; Qiao Hu; Xiuxiu Qiu; Zhiming Yao; Jingyan Fan; Lu Li; Qi Huang; Rui Zhou
Journal:  Antibiotics (Basel)       Date:  2022-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.